Earnings ·
Alnylam Reports Q3 Revenue of $1.46B and Net Income of $2.17B
ALNYAlnylam Pharmaceuticals, Inc.
Alnylam Pharmaceuticals reported third-quarter 2026 total revenues of $1,458 million, a 17% increase year-over-year, driven by a 52% surge in net product revenues to $1,292 million led by the TTR franchise. GAAP net income reached $2,167 million ($15.72 diluted EPS), significantly higher than the prior year's $293 million, primarily due to a $1.9 billion benefit from the release of valuation allowances on deferred tax assets. The company reiterated its full-year 2026 total net product revenue guidance of $4.7 billion to $5.1 billion and announced an expansion of the TRITON-CM Phase 3 study enrollment for nucresiran to 2,250 patients. Alnylam Pharmaceuticals is a biopharmaceutical company focused on developing RNA interference (RNAi) therapeutics.